A Phase 3 interventional study of Dexamethasone in Neuralgia, sponsored by Bunker Industria Farmaceutica Ltda.. Status unknown at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-07-24.
Sponsored by Bunker Industria Farmaceutica Ltda. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Neuralgia with a site in Brazil — 3 open to participants now, 4 under way, 2 of them phase 3. Neuralgia · Brazil.
Among the 21 studies in Neuralgia with a site in Brazil, this one is the 9th largest by planned enrollment, is the only one that started in 2009, is one of 8 in phase 3, and was the 2nd registered.
1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.
Browse Neuralgia studies →3 of the 21 studies in Neuralgia with a site in Brazil are open now. Recruiting first, the newest first:
Brainfarma Industria Química e Farmacêutica S/A · Sites in Brazil
Ages 18–75
EMS · Sites in Brazil
Ages 18+
Hospital da Polícia Militar de Goiás · Sites in Brazil
Ages 18+
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 154 Neuralgia studies recruiting now, 78 (51%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 104 is above the median of 52 across 833 interventional studies indexed under Neuralgia.
Median enrollment 80 across the 21 interventional studies. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 21 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Bunker Industria Farmaceutica Ltda. as lead sponsor.
Bunker Industria Farmaceutica Ltda. has 1 study filed under Neuralgia — fewer than ten, so there is no comparison to draw.
1 of the studies in Neuralgia with a site in Brazil that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07712913Phase 3Brainfarma Industria Química e Farmacêutica S/AExtended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Neuralgia with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy and tolerability of Vitatonus Dexa compared with dexamethasone in the signs and symptoms of neuralgia of various origins.
Clinical study, randomized prospective and random in nature, with a patients diagnosed with neuralgia of diverse origin.
Patients will be include in sufficient quantity to achieve the minimum of 104 evaluable patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group A: Vitatonus dexa injectable: 1 ampoule intramuscularly every 3 days for 10 days. Group B: Vitatonus DEXA tablet: 1 tablet orally every 8 hours for 10 days.
Drug: Dexamethasone
Group C: Dexamethasone Injectable: 1 ampoule intramuscularly every 3 days for 10 days. Group D: Dexamethasone tablet: 1 tablet orally every 8 hours for 10 days.
Drug: Dexamethasone
Group A: Vitatonus DEXA injectable: 1 ampoule intramuscularly every 3 days for 10 days. Group B: Vitatonus DEXA tablets: 1 tablet orally every 8 hours for 10 days. Group C: Dexamethasone Injectable: 1 ampoule intramuscularly every 3 days for 10 days. Group D: Dexamethasone tablets: 1 tablet orally every 8 hours for 10 days.
Also known as: Vitatonus dexa tablest, Vitatonus Dexa Injectable
Observation of adverse events related to medication. The causality of adverse events concerning the use of medication will be given after applying the Naranjo Algorythm
Time frame: Ten days
Efficacy evaluation Likert scale and Visual Analogue
Time frame: Ten days
The record gives a start of Oct 2009, a primary completion of Nov 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone